William L. Read

6.8k total citations · 1 hit paper
53 papers, 2.5k citations indexed

About

William L. Read is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, William L. Read has authored 53 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in William L. Read's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (9 papers) and Cancer Treatment and Pharmacology (8 papers). William L. Read is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (9 papers) and Cancer Treatment and Pharmacology (8 papers). William L. Read collaborates with scholars based in United States, Switzerland and France. William L. Read's co-authors include Ramaswamy Govindan, Nathan Page, Jay F. Piccirillo, Ryan M. Tierney, Edward L. Spitznagel, Daniel Morgensztern, Anna Vlahiotis, Jack W. Crowell, Joel Picus and Joanne Mortimer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

William L. Read

50 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

2006 1.5k citations Ramaswamy Govindan, Nathan Page et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William L. Read United States	18	1.6k	1.1k	923	633	184	53	2.5k
Hiroaki Okamoto Japan	30	1.9k 1.2×	1.6k 1.5×	812 0.9×	810 1.3×	285 1.5×	191	3.2k
Jean-Louis Pujol France	32	2.1k 1.3×	1.4k 1.4×	961 1.0×	903 1.4×	260 1.4×	138	3.4k
William J. Maples United States	24	1.5k 0.9×	477 0.5×	660 0.7×	841 1.3×	168 0.9×	50	2.6k
Michael S. Rabin United States	27	1.9k 1.2×	2.3k 2.1×	255 0.3×	654 1.0×	419 2.3×	86	3.2k
Marie Christine Aubry United States	29	1.3k 0.8×	1.4k 1.3×	375 0.4×	598 0.9×	368 2.0×	102	2.9k
Gerrit DeBoer Canada	26	1.1k 0.7×	965 0.9×	477 0.5×	755 1.2×	352 1.9×	43	2.8k
András Khoór United States	26	530 0.3×	1.1k 1.1×	343 0.4×	826 1.3×	194 1.1×	84	2.3k
Kazuhiko Yamada Japan	25	1.4k 0.9×	952 0.9×	269 0.3×	573 0.9×	321 1.7×	121	2.6k
Diana N. Ionescu Canada	26	893 0.6×	1.1k 1.1×	330 0.4×	625 1.0×	466 2.5×	78	2.7k
Chi Lin United States	26	851 0.5×	728 0.7×	309 0.3×	310 0.5×	284 1.5×	144	2.1k

Countries citing papers authored by William L. Read

Since Specialization

Citations

This map shows the geographic impact of William L. Read's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William L. Read with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William L. Read more than expected).

Fields of papers citing papers by William L. Read

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William L. Read. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William L. Read. The network helps show where William L. Read may publish in the future.

Co-authorship network of co-authors of William L. Read

This figure shows the co-authorship network connecting the top 25 collaborators of William L. Read. A scholar is included among the top collaborators of William L. Read based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William L. Read. William L. Read is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Porto, Edoardo, J. Manuel Revuelta Barbero, David A. Bray, et al.. (2023). Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas. Frontiers in Endocrinology. 14. 1195792–1195792. 4 indexed citations

Janopaul‐Naylor, James, Jeffrey M. Switchenko, Sibo Tian, et al.. (2021). Impact of Metastasectomy and Aggressive Local Therapy in Newly Diagnosed Metastatic Soft Tissue Sarcoma: An Analysis of the NCDB. Annals of Surgical Oncology. 29(1). 649–659. 3 indexed citations

Reimer, Nickolas B., et al.. (2019). Recurrent Epithelioid Hemangioma of the Bony Pelvis Responding to Propranolol. Case Reports in Oncology. 12(3). 704–708. 3 indexed citations

Switchenko, Jeffrey M., Arielle L. Heeke, Tony Pan, & William L. Read. (2019). The use of a predictive statistical model to make a virtual control arm for a clinical trial. PLoS ONE. 14(9). e0221336–e0221336. 11 indexed citations

Huang, Raymond Y., Prashin Unadkat, Wenya Linda Bi, et al.. (2018). Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro-Oncology. 21(2). 234–241. 22 indexed citations

Holdhoff, Matthias, Xiaobu Ye, Jeffrey G. Supko, et al.. (2017). Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro-Oncology. 19(6). 845–852. 43 indexed citations

Read, William L., Sumita Trivedi, & Cecilia Williams. (2017). Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases. Gynecologic Oncology Reports. 22. 75–77. 2 indexed citations

Read, William L. & Cecilia Williams. (2017). Recurrent Meningioma of the Cervical Spine, Successfully Treated with Liposomal Doxorubicin. Case Reports in Oncology. 10(2). 656–659. 5 indexed citations

McCracken, D. Jay, et al.. (2016). Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma. Journal of Neuro-Oncology. 130(1). 193–201. 20 indexed citations

10.

Kato, Shinichi, et al.. (2011). Association of human papillomavirus and squamous cell carcinoma of esophagus: A SEER database analysis.. Journal of Clinical Oncology. 29(15_suppl). e14634–e14634. 1 indexed citations

11.

Makani, Samir, Colleen L. Channick, John W. Renner, et al.. (2010). Pulmonary Langerhans Cell Histiocytosis Diagnosed in a Cervical Lymph Node. Acta Cytologica. 54(4). 618–622. 4 indexed citations

12.

Read, William L., et al.. (2009). A study of lavender and tea tree oils on postmenopausal FSH levels and hot flash severity. Journal of Clinical Oncology. 27(15_suppl). 1516–1516. 2 indexed citations

13.

Traynor, Anne M., Michael S. Gordon, Dona Alberti, et al.. (2009). A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Investigational New Drugs. 28(4). 509–515. 14 indexed citations

14.

Anthony, Stephen P., William L. Read, Peter J. Rosen, et al.. (2008). Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity. Journal of Clinical Oncology. 26(15_suppl). 2531–2531. 8 indexed citations

15.

Read, William L., Maria Q. Baggstrom, Paula M. Fracasso, & Ramaswamy Govindan. (2008). A Phase I Study of Bexarotene and Rosiglitazone in Patients with Refractory Cancers. Chemotherapy. 54(3). 236–241. 22 indexed citations

16.

Read, William L., Nathan Page, Ryan M. Tierney, Jay F. Piccirillo, & Ramaswamy Govindan. (2004). The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer. 45(2). 137–142. 87 indexed citations

17.

Govindan, Ramaswamy, William L. Read, Kathryn Trinkaus, et al.. (2003). Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.. PubMed. 17(9 Suppl 8). 27–31. 20 indexed citations

18.

Read, William L., Joanne Mortimer, & Joel Picus. (2002). Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 94(3). 847–853. 91 indexed citations

19.

Sørensen, Keld E., et al.. (1990). Lyme disease antibodies in thoroughbred broodmares. correlation to early pregnancy failure. Journal of Equine Veterinary Science. 10(3). 166–168. 11 indexed citations

20.

Read, William L.. (1988). Colon: Relationship between Epithelial Transport and Motility. Pharmacology. 36(1). 120–125. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact